SOURCE: MMIT Analytics, as of 7/3/19
Monday, July 8, 2019
The FDA on June 28 approved Pfizer’s...
...Zirabev, a biosimilar to
Roche's blockbuster cancer treatment Avastin. For the treatment of ovarian,
colorectal and kidney cancer, Avastin currently holds preferred status for 13%
of covered lives, growing to 19% with prior authorization and/or step therapy.
Overall, the drug is covered under the pharmacy benefit only for 38% of covered
lives.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment